Allosteric Sensitization of Nicotinic Receptors by Galantamine, a New Treatment Strategy for Alzheimer’s Disease

The cholinergic hypothesis of geriatric memory dysfunction

Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545 · see citing works

The cholinergic hypothesis of Alzheimer’s disease: A review of progress

Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198 · see citing works

Linkage of a neurophysiological deficit in schizophrenia to a chromosome 15 locus

Freedman, R., Coon, H., Myles-Worsley, M., Orr-Urtreger, A., Olincy, A., Davis, A., Polymeropoulos, M., Holik, J., Hopkins, J., Hoff, M., et al. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.2.587 · Cited by 1,141 · see citing works

A missense mutation in the neuronal nicotinic acetylcholine receptor α4 subunit is associated with autosomal dominant nocturnal frontal lobe epilepsy

Steinlein, O. K., Mulley, J. C., Propping, P., Wallace, R. H., Phillips, H. A., Sutherland, G. R., Scheffer, I. E., & Berkovic, S. F. (1995) · Nature Genetics · doi:10.1038/ng1095-201 · Cited by 1,134 · see citing works

β-Amyloid1–42 Binds to α7 Nicotinic Acetylcholine Receptor with High Affinity

Wang, H.-Y., Lee, D. H. S., D’Andrea, M. R., Peterson, P. A., Shank, R. P., & Reitz, A. B. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.8.5626 · Cited by 818 · see citing works

Handbook of Experimental Pharmacology, vol 14.

Freedman, A. D. (1972) · Archives of Internal Medicine · doi:10.1001/archinte.1972.03650020118031 · Cited by 777 · see citing works

Pharmacology of Nicotine: Addiction and Therapeutics

Benowitz, N. L. (1996) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.36.040196.003121 · Cited by 589 · see citing works

Acute stress facilitates long-lasting changes in cholinergic gene expression

Kaufer, D., Friedman, A., Seidman, S., & Soreq, H. (1998) · Nature · doi:10.1038/30741 · Cited by 588 · see citing works

Nicotine binding and nicotinic receptor subunit RNA after chronic nicotine treatment

Marks, M., Pauly, Jr., Gross, S., Deneris, E., Hermans-Borgmeyer, I., Heinemann, S., & Collins, A. (1992) · The Journal of Neuroscience · doi:10.1523/jneurosci.12-07-02765.1992 · Cited by 551 · see citing works

Basal forebrain neurons in the dementia of Parkinson disease

Whitehouse, P. J., Hedreen, J. C., White, C. L., & Price, D. L. (1983) · Annals of Neurology · doi:10.1002/ana.410130304 · Cited by 535 · see citing works

Nicotinic acetylcholine binding sites in Alzheimer's disease

Whitehouse, P. J., Martino, A. M., Antuono, P., Lowenstein, P. R., Coyle, J. T., Price, D. L., & Kellar, K. J. (1986) · Brain Research · doi:10.1016/0006-8993(86)90819-x · Cited by 485 · see citing works

Nicotinic acetylcholine receptors in health and disease

Lindstrom, J. (1997) · Molecular Neurobiology · doi:10.1007/bf02740634 · Cited by 443 · see citing works

Transmitter leakage from motor nerve endings

Katz, B., & Miledi, R. (1977) · Proceedings of the Royal Society B Biological Sciences · doi:10.1098/rspb.1977.0029 · Cited by 442 · see citing works

Choline is a Selective Agonist of α7 Nicotinic Acetylcholine Receptors in the Rat Brain Neurons

Alkondon, M., Pereira, E. F. R., Cartes, W. S., Maelicke, A., & Albuquerque, E. X. (1997) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1997.tb01702.x · Cited by 441 · see citing works

Properties of Neuronal Nicotinic Acetylcholine Receptors: Pharmacological Characterization and Modulation of Synaptic Function,

Albuquerque, E. X., Alkondon, M., Pereira, E. F. R., Castro, N. G., Schrattenholz, A. S., Barbosa, C. T. F., Bonfante-Cabarcas, R. A., Aracava, Y., Eisenberg, H. M., & Maelicke, A. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36503-6 · Cited by 436 · see citing works

Chimaeric nicotinic–serotonergic receptor combines distinct ligand binding and channel specificities

Eiselé, J.-L., Bertrand, S., Galzi, J., Devillers‐Thiéry, A., Changeux, J., & Bertrand, D. (1993) · Nature · doi:10.1038/366479a0 · Cited by 405 · see citing works

Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology

Perry, E. K., Morris, C. M., COURT, J. A., Cheng, A. V., FAIRBAIRN, A. F., McKeith, I. G., Irving, D., Brown, A. J., & Perry, R. H. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00410-7 · Cited by 386 · see citing works

Cholinesterase Inhibitors in the Treatment of Alzheimer??s Disease

Nordberg, A. K., & Svensson, A. (1998) · Drug Safety · doi:10.2165/00002018-199819060-00004 · Cited by 381 · see citing works

Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies

Perry, D. C., Dávila-Garcı́a, M. I., Stockmeier, C. A., & Kellar, K. J. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38304-1 · Cited by 362 · see citing works

Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains

Nordberg, A. K., & Winblad, B. G. (1986) · Neuroscience Letters · doi:10.1016/0304-3940(86)90629-4 · Cited by 361 · see citing works

Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer disease

Levey, A. I. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.24.13541 · Cited by 359 · see citing works

Choline and Selective Antagonists Identify Two Subtypes of Nicotinic Acetylcholine Receptors that Modulate GABA Release from CA1 Interneurons in Rat Hippocampal Slices

Alkondon, M., Pereira, E. F. R., Eisenberg, H. M., & Albuquerque, E. X. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-07-02693.1999 · Cited by 332 · see citing works

Ivermectin: A Positive Allosteric Effector of the α7 Neuronal Nicotinic Acetylcholine Receptor

Krause, R. M., Buisson, B., Bertrand, S., Corringer, P., Galzi, J., Changeux, J., & Bertrand, D. (1998) · Molecular Pharmacology · doi:10.1124/mol.53.2.283 · Cited by 320 · see citing works

Intravenous nicotine in Alzheimer's disease: a pilot study

NEWHOUSE, P. A., Sunderland, T., Tariot, P. N., Blumhardt, C. L., Weingartner, H., Mellow, A. M., & Murphy, D. L. (1988) · Psychopharmacology · doi:10.1007/bf00174504 · Cited by 308 · see citing works

Cigarette smoking and major depression

Covey, L. S., Glassman, A. H., & Stetner, F. (1998) · Journal of Addictive Diseases · doi:10.1300/j069v17n01_04 · Cited by 302 · see citing works

alpha-Bungarotoxin-sensitive hippocampal nicotinic receptor channel has a high calcium permeability

Castro, N. G., & Albuquerque, E. X. (1995) · Biophysical Journal · doi:10.1016/s0006-3495(95)80213-4 · Cited by 273 · see citing works

Nicotinic System Involvement in Alzheimer??s and Parkinson??s Diseases

NEWHOUSE, P. A., Potter, A., & Levin, E. D. (1997) · Drugs & Aging · doi:10.2165/00002512-199711030-00005 · Cited by 266 · see citing works

Nicotinic Receptor Activation in Human Cerebral Cortical Interneurons: a Mechanism for Inhibition and Disinhibition of Neuronal Networks

Alkondon, M., Pereira, E. F. R., Eisenberg, H. M., & Albuquerque, E. X. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-01-00066.2000 · Cited by 248 · see citing works

Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands.

Schrattenholz, A. S., Pereira, E. F. R., Roth, U., Weber, K. H., Albuquerque, E. X., & Maelicke, A. (1996) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)08675-4 · Cited by 226 · see citing works

Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease

Maelicke, A., & Albuquerque, E. X. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00093-5 · Cited by 222 · see citing works

Nicotine Prevents Experimental Parkinsonism in Rodents and Induces Striatal Increase of Neurotrophic Factors

Maggio, R., Riva, M. A., Vaglini, F., Fornai, F., Molteni, R., Armogida, M., Racagni, G., & Corsini, G. U. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.71062439.x · Cited by 218 · see citing works

Kinetic Analysis of Regional (S)(-)11C-Nicotine Binding in Normal and Alzheimer Brains In Vivo Assessment Using Positron Emission Tomography

Nordberg, A. K., Lundqvist, H., Hartvig, P., Lilja, A., & Långström, B. (1995) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199505000-00006 · Cited by 212 · see citing works

Effects of Nicotine on Biological Systems II

Clarke, P. B. S., Quik, M., Adlkofer, F. X., & Thurau, K. (1995) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7445-8 · Cited by 202 · see citing works

Nicotine patches in Alzheimer's disease: Pilot study on learning, memory, and safety

Wilson, A. L., Langley, L. K., Monley, J., Bauer, T., Rottunda, S. J., McFalls, E. O., Kovera, C. A., & McCarten, J. R. (1995) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(95)00043-v · Cited by 196 · see citing works

α4 but Not α3 and α7 Nicotinic Acetylcholine Receptor Subunits Are Lost from the Temporal Cortex in Alzheimer's Disease

Martin-Ruiz, C. M., COURT, J. A., Molnár, E., Lee, M., Gotti, C., Mamalaki, A., Tsouloufis, T., Tzartos, S. J., Ballard, C. G., Perry, R. H., et al. (1999) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1999.0731635.x · Cited by 194 · see citing works

Stimulation of α4β2 nicotinic acetylcholine receptors inhibits β-amyloid toxicity

Kihara, T., Shimohama, S., Urushitani, M., Sawada, H., Kimura, J., Kume, T., Maeda, T., & AKAIKE, A. (1998) · Brain Research · doi:10.1016/s0006-8993(98)00138-3 · Cited by 193 · see citing works

Chronic Nicotine Treatment Up-Regulates α3 and α7 Acetylcholine Receptor Subtypes Expressed by the Human Neuroblastoma Cell Line SH-SY5Y

Peng, X.-D., Gerzanich, V., Anand, R., Wang, F., & Lindstrom, J. M. (1997) · Molecular Pharmacology · doi:10.1124/mol.51.5.776 · Cited by 191 · see citing works

Acute effects of the selective cholinergic channel activator (nicotinic agonist) ABT-418 in Alzheimer's disease

Potter, A., Corwin, J., Lang, J., Piasecki, M., Lenox, R., & Newhouse, P. A. (1999) · Psychopharmacology · doi:10.1007/s002130050897 · Cited by 163 · see citing works

Potentiation and Inhibition of Neuronal Nicotinic Receptors by Atropine: Competitive and Noncompetitive Effects

Zwart, R., & Vijverberg, H. P. M. (1997) · Molecular Pharmacology · doi:10.1124/mol.52.5.886 · Cited by 157 · see citing works

Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR

Samochocki, M., Zerlin, M., Jostock, R., Groot‐Kormelink, P. J., Luyten, W. H. M. L., Albuquerque, E. X., & Maelicke, A. (2000) · Acta Neurologica Scandinavica · doi:10.1034/j.1600-0404.2000.00310.x · Cited by 151 · see citing works

Epibatidine and ABT 418 reveal selective losses of α4β2 nicotinic receptors in Alzheimer brains

Berglund, U. W., & Nordberg, A. K. (1995) · Neuroreport · doi:10.1097/00001756-199511270-00033 · Cited by 148 · see citing works

Nicotinic cholinoceptive neurons of the frontal cortex are reduced in Alzheimer's disease

Schro¨der, H., Ezio, G., Struble, R. G., Zilles, K., & Maelicke, A. (1991) · Neurobiology of Aging · doi:10.1016/0197-4580(91)90107-u · Cited by 148 · see citing works

Age-Related Effects of the Nicotinic Antagonist Mecamylamine on Cognition and Behavior

NEWHOUSE, P. A., Potter, A., Corwin, J., & Lenox, R. H. (1994) · Neuropsychopharmacology · doi:10.1038/npp.1994.11 · Cited by 136 · see citing works

The reversible cholinesterase inhibitor physostigmine has channel-blocking and agonist effects on the acetylcholine receptor-ion channel complex.

Shaw, K. P., Aracava, Y., AKAIKE, A., Daly, J. W., Rickett, D. L., & Albuquerque, E. X. (1985) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)14185-0 · Cited by 136 · see citing works

Identification and functional characterization of a new agonist site on nicotinic acetylcholine receptors of cultured hippocampal neurons.

Pereira, E. F. R., Reinhardt-Maelicke, S., Schrattenholz, A. S., Maelicke, A., & Albuquerque, E. X. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38284-4 · Cited by 125 · see citing works

Physostigmine, galanthamine and codeine act as ‘noncompetitive nicotinic receptor agonists’ on clonal rat pheochromocytoma cells

Storch, A., Schrattenholz, A. S., Cooper, J. C., Ghani, E. M. A., Gutbrod, O., Weber, K. H., Reinhardt, S., Lobron, C., Hermsen, B., Šoškić, V., et al. (1995) · European Journal of Pharmacology Molecular Pharmacology · doi:10.1016/0922-4106(95)00080-1 · Cited by 116 · see citing works

Physostigmine and galanthamine: probes for a novel binding site on the alpha 4 beta 2 subtype of neuronal nicotinic acetylcholine receptors stably expressed in fibroblast cells.

Pereira, E. F. R., Alkondon, M., Reinhardt, S., Maelicke, A., Peng, X., Lindström, J., Whiting, P. J., & Albuquerque, E. X. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)22435-1 · Cited by 108 · see citing works

Cholinergic underactivity in human memory disorders

Davis, K. L., & Yamamura, H. I. (1978) · Life Sciences · doi:10.1016/0024-3205(78)90100-5 · Cited by 104 · see citing works

α7 Nicotinic acetylcholine receptors and modulation of gabaergic synaptic transmission in the hippocampus

Alkondon, M., Braga, M. F. M., Pereira, E. F. R., Maelicke, A., & Albuquerque, E. X. (2000) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00006-6 · Cited by 102 · see citing works

Nicotinic receptor: an allosteric protein specialized for intercellular communication

Bertrand, D., & Changeux, J. (1995) · Seminars in Neuroscience · doi:10.1006/smns.1995.0010 · Cited by 94 · see citing works

New approach to drug therapy in Alzheimer's dementia Alfred Maelicke and Edson X. Albuquerque

Maelicke, A., & Albuquerque, E. X. (1996) · Drug Discovery Today · doi:10.1016/1359-6446(96)89089-1 · Cited by 94 · see citing works

Photoaffinity labeling of Torpedo acetylcholine receptor by physostigmine

Schrattenholz, A. S., Godovac‐Zimmermann, J., Schäfer, H., Albuquerque, E. X., & Maelicke, A. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb18187.x · Cited by 80 · see citing works

A 24-week randomized trial of controlled-release physostigmine in patients with Alzheimer’s disease

Thal, L. J., Ferguson, J. M., Mintzer, J. E., Raskin, A., & Targum, S. D. (1999) · Neurology · doi:10.1212/wnl.52.6.1146 · Cited by 74 · see citing works

Kinetic Properties and Regulation of GABAA Receptor Channels

Macdonald, R. L., & Twyman, R. E. (1992) · Springer eBooks · doi:10.1007/978-1-4615-3328-3_10 · Cited by 72 · see citing works

Ligand Binding and Activation of Rat Nicotinic α4β2 Receptors Stably Expressed in HEK293 Cells

Sabey, K., Paradiso, K. G., Zhang, J., & Steinbach, J. H. (1999) · Molecular Pharmacology · doi:10.1124/mol.55.1.58 · Cited by 66 · see citing works

The hypothesis of an ambient level of acetylcholine in the central nervous system

Descarries, L. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80013-2 · Cited by 58 · see citing works

Biochemical Aspects of Cholinergic Excitation

Maelicke, A. (1984) · Angewandte Chemie International Edition in English · doi:10.1002/anie.198401951 · Cited by 58 · see citing works

NBD-5-acylcholine: fluorescent analog of acetylcholine and agonist at the neuromuscular junction.

Jürss, R., Prinz, H., & Maelicke, A. (1979) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.76.3.1064 · Cited by 57 · see citing works

Monoclonal antibodies FK1 and WF6 define two neighboring ligand binding sites on Torpedo acetylcholine receptor alpha-polypeptide.

Schröder, B., Reinhardt-Maelicke, S., Schrattenholz, A. S., McLane, K. E., Kretschmer, A., Conti-Tronconi, B. M., & Maelicke, A. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)34075-9 · Cited by 56 · see citing works

Chapter 35 The role of nicotinic receptors in the pathophysiology ofAlzheimer's disease

Nordberg, A. K., Nilsson-Håkansson, L., Adem, A., Hardy, J., Alafuzoff, I. I., Lai, Z., Herrera‐Marschitz, M., & Winblad, B. G. (1989) · Progress in brain research · doi:10.1016/s0079-6123(08)62495-4 · Cited by 56 · see citing works

Presynaptic Muscarinic Receptors in the Central Nervous Systema

Raiteri, M., Marchi, M., & Paudice, P. (1990) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1990.tb31987.x · Cited by 54 · see citing works

Differential effects of transdermal nicotine on microstructured analyses of tics in Tourette's syndrome: an open study

DURSUN, S. M., & Reveley, M. A. (1997) · Psychological Medicine · doi:10.1017/s0033291796003984 · Cited by 46 · see citing works

Tacrine interacts with an allosteric activator site on α4β2 nAChRs in M10 cells

Svensson, A., & Nordberg, A. K. (1996) · Neuroreport · doi:10.1097/00001756-199609020-00029 · Cited by 37 · see citing works

The cholinergic hypothesis of Alzheimer's disease

Siegfried, K. (1993) · European Neuropsychopharmacology · doi:10.1016/0924-977x(93)90007-9 · Cited by 36 · see citing works

Nicotine reverses scopolamine-induced impairment of performance in passive avoidance task in rats through its action on the dopaminergic neuronal system

Nitta, A., Katono, Y., Itoh, A., Hasegawa, T., & NABESHIMA, T. (1994) · Pharmacology Biochemistry and Behavior · doi:10.1016/0091-3057(94)90227-5 · Cited by 34 · see citing works

Correlation of nicotinic binding with neurochemical markers in Alzheimer's disease

Sabbagh, M. N., Reid, R. T., Corey‐Bloom, J., Rao, T. S., Hansen, L. A., Alford, M. F., Masliah, E., Adem, A., Lloyd, G. K., & Thal, L. J. (1998) · Journal of Neural Transmission · doi:10.1007/s007020050090 · Cited by 34 · see citing works

Allosteric modulation of neuronal nicotinic acetylcholine receptors

Buisson, B., & Bertrand, D. (1998) · Journal of Physiology-Paris · doi:10.1016/s0928-4257(98)80144-7 · Cited by 31 · see citing works

Enhancement of glycine release from human brain cortex synaptosomes by acetylcholine acting at M4 muscarinic receptors.

Russo, C., Marchi, M., Andrioli, G. C., Cavazzani, P., & Raiteri, M. (1993) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38334-5 · Cited by 30 · see citing works

Modulatory control by non-competitive agonists of nicotinic cholinergic neurotransmission in the central nervous system

Maelicke, A., Schrattenholz, A. S., & Schröder, H. (1995) · Seminars in Neuroscience · doi:10.1006/smns.1995.0012 · Cited by 28 · see citing works

Stable expression in HEK‐293 cells of the rat α3/β4 subtype of neuronal nicotinic acetylcholine receptor

Stetzer, E., Ebbinghaus, U., Storch, A., Poteur, L., Schrattenholz, A. S., Kramer, G., Methfessel, C., & Maelicke, A. (1996) · FEBS Letters · doi:10.1016/s0014-5793(96)01115-5 · Cited by 27 · see citing works

Transdermal Nicotine in Tourette’s Syndrome

Silver, A. A., Shytle, R. D., Philipp, M. K., & Sanberg, P. R. (1995) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7445-8_38 · Cited by 26 · see citing works

Pharmacology of Nicotine

Benowitz, N. L. (1998) · Springer eBooks · doi:10.1007/978-1-4757-2913-9_20 · Cited by 21 · see citing works

Effects of nicotine on biological systems II

Jensen, E. J. (1996) · Respiratory Medicine · doi:10.1016/s0954-6111(96)90295-4 · Cited by 21 · see citing works

Nicotine: not just for cigarettes anymore

Wonnacott, S., & Marks, M. J. (1999) · Drug Discovery Today · doi:10.1016/s1359-6446(99)01413-0 · Cited by 8 · see citing works

Pentobarbital regulation of the kinetic properties of GABA receptor chloride channels.

Rl, M., Re, T., Cj, R., & Weddle, M. G. (1988) · PubMed · Cited by 8 · see citing works

Neuronal Nicotinic Receptors and Synaptic Transmission in the Mammalian Central Nervous System

Albuquerque, E. X., Pereira, E. F. R., Alkondon, M., Eisenberg, H. M., & Maelicke, A. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57079-7_13 · Cited by 4 · see citing works

Neuronal Nicotinic Acetylcholine Receptors in Non-neuronal Cells, Expression and Renaturation of Ligand Binding Domain, and Modulatory Control by Allosterically Acting Ligands

Maelicke, A., Schrattenholz, A. S., & Albuquerque, E. X. (2000) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-57079-7_18 · Cited by 3 · see citing works

Alzheimer’s disease

Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569 · see citing works

Nicotinic Acetylcholine Receptors and Nicotinic Cholinergic Mechanisms of the Central Nervous System

Dani, J. A., & Bertrand, D. (2007) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.47.120505.105214 · Cited by 1,197 · see citing works

Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs

Miyamoto, S., Duncan, G. E., Marx, C. E., & Lieberman, J. A. (2005) · Molecular Psychiatry · doi:10.1038/sj.mp.4001556 · Cited by 988 · see citing works

Nicotinic acetylcholine receptors: from structure to brain function

Hogg, R. C., Raggenbass, M., & Bertrand, D. (2003) · Springer eBooks · doi:10.1007/s10254-003-0005-1 · Cited by 529 · see citing works

Nicotinic ACh receptors as therapeutic targets in CNS disorders

Dineley, K. T., Pandya, A. A., & Yakel, J. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.002 · Cited by 449 · see citing works

Amaryllidaceae and Sceletium alkaloids

Jin, Z. (2013) · Natural Product Reports · doi:10.1039/c3np70005d · Cited by 409 · see citing works

Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors

Jann, M. W., Shirley, K. L., & Small, G. W. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241100-00003 · Cited by 365 · see citing works

Acetylcholinesterase inhibitory activity of some Amaryllidaceae alkaloids and Narcissus extracts

López, S., Bastida, J., Viladomat, F., & Codina, C. J. (2002) · Life Sciences · doi:10.1016/s0024-3205(02)02034-9 · Cited by 359 · see citing works

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Samochocki, M., Höffle‐Maas, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E. F. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045773 · Cited by 345 · see citing works

Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease

Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309 · see citing works

Synthesis and Pharmacology of Galantamine

Marco, J. L., Carreiras, M. C., Rodríguez, C., Villarroya, M., & Garcı́a, A. G. (2005) · Chemical Reviews · doi:10.1021/cr040415t · Cited by 296 · see citing works

Pharmacologic treatments of dementia

Bonner, L. T., & Peskind, E. R. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00007-x · Cited by 225 · see citing works

Nicotinic Acetylcholine Receptor-Mediated Neuroprotection by Donepezil Against Glutamate Neurotoxicity in Rat Cortical Neurons

Takada, Y., Yonezawa, A., Kume, T., Katsuki, H., Kaneko, S., Sugimoto, H., & Akaike, A. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.050104 · Cited by 209 · see citing works

Mechanisms of Neuroprotective Effects of Nicotine and Acetylcholinesterase Inhibitors: Role of α4 and α7 Receptors in Neuroprotection

Akaike, A., Takada‐Takatori, Y., Kume, T., & Izumi, Y. (2009) · Journal of Molecular Neuroscience · doi:10.1007/s12031-009-9236-1 · Cited by 200 · see citing works

Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease

Agis-Torres, A., Sollhuber, M., Fernandez, M., & Sanchez-Montero, J. M. (2014) · Current Neuropharmacology · doi:10.2174/1570159x113116660047 · Cited by 202 · see citing works

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders

Sacco, K. A., Bannon, K. L., & George, T. P. (2004) · Journal of Psychopharmacology · doi:10.1177/0269881104047273 · Cited by 201 · see citing works

Regulation of synaptic transmission and plasticity by neuronal nicotinic acetylcholine receptors

McKay, B. E., Placzek, A. N., & Dani, J. A. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.001 · Cited by 181 · see citing works

Galantamine-induced Amyloid-β Clearance Mediated via Stimulation of Microglial Nicotinic Acetylcholine Receptors

Takata, K., Kitamura, Y., Saeki, M., Terada, M., Kagitani, S., Kitamura, R., Fujikawa, Y., Maelicke, A., Tomimoto, H., Taniguchi, T., et al. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.142356 · Cited by 176 · see citing works

Dementia of the Alzheimer Type

Jalbert, J. J., Daiello, L. A., & Lapane, K. L. (2008) · Epidemiologic Reviews · doi:10.1093/epirev/mxn008 · Cited by 174 · see citing works

Nicotine aversion: Neurobiological mechanisms and relevance to tobacco dependence vulnerability

Fowler, C. D., & Kenny, P. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2013.09.008 · Cited by 167 · see citing works

A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia

Friedman, J. I., Adler, D. N., Howanitz, E. M., Harvey, P. D., Brenner, G. H., Temporini, H. D., WHITE, L. E., & Parrella, M. J. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01342-7 · Cited by 168 · see citing works

Cholinesterase inhibitors in the treatment of dementia.

Ellis, J. M. (2005) · PubMed · Cited by 159 · see citing works

Nicotinic receptor agonists as neuroprotective/neurotrophic drugs. Progress in molecular mechanisms

Mudò, G., Belluardo, N., & Fuxé, K. (2006) · Journal of Neural Transmission · doi:10.1007/s00702-006-0561-z · Cited by 156 · see citing works

Sustained cholinesterase inhibition in AD patients receiving rivastigmine for 12 months

Darreh‐Shori, T., Almkvist, O., Guan, Z. Z., Garlind, A., Strandberg, B., Svensson, A., Soreq, H., Hellström‐Lindahl, E., & Nordberg, A. K. (2002) · Neurology · doi:10.1212/wnl.59.4.563 · Cited by 154 · see citing works

Galantamine Slows Down Plaque Formation and Behavioral Decline in the 5XFAD Mouse Model of Alzheimer’s Disease

Bhattacharya, S., Haertel, C., Maelicke, A., & Montag, D. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089454 · Cited by 142 · see citing works

Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone

Schubert, M., Young, K. A., & Hicks, P. B. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.04.006 · Cited by 140 · see citing works

Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, <i>in vitro</i> and <i>in vivo</i> evaluations

Misra, S., Chopra, K., Sinha, V. R., & Medhi, B. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1089956 · Cited by 136 · see citing works

Clinical Pharmacokinetics of Galantamine

Farlow, M. R. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342150-00005 · Cited by 134 · see citing works

Galantamine Enhances Dopaminergic Neurotransmission In Vivo Via Allosteric Potentiation of Nicotinic Acetylcholine Receptors

Schilström, B., Ivanov, V., Wiker, C., & Svensson, T. H. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301087 · Cited by 128 · see citing works

Nicotinic Acetylcholine Receptors at Glutamate Synapses Facilitate Long-Term Depression or Potentiation

Ge, S., & Dani, J. A. (2005) · Journal of Neuroscience · doi:10.1523/jneurosci.0542-05.2005 · Cited by 125 · see citing works

Galantamine modulates nicotinic receptor and blocks Aβ-enhanced glutamate toxicity

Kihara, T., Sawada, H., Nakamizo, T., Kanki, R., Yamashita, H., Maelicke, A., & Shimohama, S. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.132 · Cited by 124 · see citing works

Cholinergic Drugs for Alzheimer's Disease Enhance in Vitro Dopamine Release

Zhang, L., Zhou, F.-M., & Dani, J. A. (2004) · Molecular Pharmacology · doi:10.1124/mol.104.000299 · Cited by 121 · see citing works

Does kynurenic acid act on nicotinic receptors? An assessment of the evidence

Stone, T. W. (2019) · Journal of Neurochemistry · doi:10.1111/jnc.14907 · Cited by 119 · see citing works

Pharmacological Aspects of the Acetylcholinesterase Inhibitor Galantamine

Ago, Y., Koda, K., Takuma, K., & Matsuda, T. (2011) · Journal of Pharmacological Sciences · doi:10.1254/jphs.11r01cr · Cited by 116 · see citing works

Cholinergic nicotinic receptors: Competitive ligands, allosteric modulators, and their potential applications

Romanelli, M. N., & Gualtieri, F. (2003) · Medicinal Research Reviews · doi:10.1002/med.10037 · Cited by 112 · see citing works

Stimulating Nicotinic Receptors Trigger Multiple Pathways Attenuating Cytotoxicity in Models of Alzheimer's and Parkinson's Diseases

Kawamata, J., & Shimohama, S. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2011-110173 · Cited by 111 · see citing works

β-Amyloid Directly Inhibits Human α4β2-Nicotinic Acetylcholine Receptors Heterologously Expressed in Human SH-EP1 Cells

Wu, J., Kuo, Y., George, A. A., Xu, L., Hu, J., & Lukas, R. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400335200 · Cited by 112 · see citing works

Galantamine for Alzheimer's disease

Prvulovic, D., Hampel, H. J., & Pantel, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425251003592137 · Cited by 110 · see citing works

Effects of Cholinesterase Inhibitors on the Activities and Protein Levels of Cholinesterases in the Cerebrospinal Fluid of Patients with Alzheimers Disease: A Review of Recent Clinical Studies

Darreh‐Shori, T., & Soininen, H. S. (2010) · Current Alzheimer Research · doi:10.2174/156720510790274455 · Cited by 106 · see citing works

Nicotinic receptors and schizophrenia

Ripoll, N., Grall‐Bronnec, M., & Bourin, M. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125004060 · Cited by 106 · see citing works

Plant Sources of Galanthamine: Phytochemical and Biotechnological Aspects

Berkov, S. H., Georgieva, L., Kondakova, V., Atanassov, A. I., Viladomat, F., Bastida, J., & Codina, C. J. (2009) · Biotechnology & Biotechnological Equipment · doi:10.1080/13102818.2009.10817633 · Cited by 105 · see citing works

PET imaging of the in vivo brain acetylcholinesterase activity and nicotine binding in galantamine-treated patients with AD

Kadir, A., Darreh‐Shori, T., Almkvist, O., Wall, A., Grut, M., Strandberg, B., Ringheim, A., Eriksson, B., Blomquist, G., Långström, B., et al. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.02.020 · Cited by 103 · see citing works

PET Neuroimaging of Alzheimer's Disease: Radiotracers and Their Utility in Clinical Research

Bao, W., Xie, F., Zuo, C., Guan, Y., & Huang, Y. H. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.624330 · Cited by 102 · see citing works

Cholinergic imaging in dementia spectrum disorders

Roy, R., Niccolini, F., Pagano, G., & Politis, M. (2016) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-016-3349-x · Cited by 101 · see citing works

Recent advancements in the field of nanotechnology for the delivery of anti-Alzheimer drug in the brain region

Agrawal, M., Saraf, S., Saraf, S., Antimisiaris, S. G., Hamano, N., Li, S., Chougule, M. B., Shoyele, S., Gupta, U. D., Ajazuddin, M., et al. (2018) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2018.1471058 · Cited by 100 · see citing works

Nicotinic receptor mechanisms and cognition in normal states and neuropsychiatric disorders

Sacco, K. A., Bannon, K. L., & George, T. P. (2004) · Journal of Psychopharmacology · doi:10.1177/026988110401800403 · Cited by 100 · see citing works

Antioxidant, anti-diabetic, acetylcholinesterase inhibitory potential and estimation of alkaloids (lycorine and galanthamine) from Crinum species: An important source of anticancer and anti-Alzheimer drug

Ghane, S. G., Attar, U. A., Yadav, P. B., & Lekhak, M. M. (2018) · Industrial Crops and Products · doi:10.1016/j.indcrop.2018.08.087 · Cited by 99 · see citing works

Effect of R3487/MEM3454, a novel nicotinic alpha7 receptor partial agonist and 5-HT3 antagonist on sustained attention in rats.

Rezvani, A., Kholdebarin, E., Brucato, F., Callahan, P., Lowe, D., & Levin, E. (2009) · Progress in Neuro-psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2008.11.018 · Cited by 97 · see citing works

Disease-Modifying Therapies in Alzheimer???s Disease

ll, M. H., Berger, T., & Heneka, M. T. (2006) · Drugs · doi:10.2165/00003495-200666160-00004 · Cited by 94 · see citing works

Clinically Significant Drug Interactions with Cholinesterase Inhibitors

Bentu??-Ferrer, D., Tribut, O., Polard, É., & Allain, H. (2003) · CNS Drugs · doi:10.2165/00023210-200317130-00002 · Cited by 92 · see citing works

Calcium channelopathies and Alzheimer's disease: Insight into therapeutic success and failures

Chakroborty, S., & Stutzmann, G. E. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.11.012 · Cited by 91 · see citing works

Positive modulators of the α7 nicotinic receptor against neuroinflammation and cognitive impairment in Alzheimer's disease

Echeverrı́a, V., Iarkov, A., & Aliev, G. (2016) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2016.01.002 · Cited by 91 · see citing works

AProspective, Open-Label Trial of Galantamine in Autistic Disorder

Nicolson, R., Craven‐Thuss, B., & Smith, J. (2006) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2006.16.621 · Cited by 90 · see citing works

Biophysical alterations of hippocampal pyramidal neurons in learning, ageing and Alzheimer's disease

Disterhoft, J. F., Wu, W., & Ohno, M. (2004) · Ageing Research Reviews · doi:10.1016/j.arr.2004.07.001 · Cited by 88 · see citing works

Cholinergic systems in progressive supranuclear palsy

Warren, N. (2004) · Brain · doi:10.1093/brain/awh391 · Cited by 89 · see citing works

Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years

Bullock, R. M., & Dengiz, A. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00562.x · Cited by 87 · see citing works

Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial

Ghaleiha, A., Ghyasvand, M., Mohammadi, M.-R., Farokhnia, M., Yadegari, N., Tabrizi, M. H., Hajiaghaee, R., Yekehtaz, H., & Akhondzadeh, S. (2013) · Journal of Psychopharmacology · doi:10.1177/0269881113508830 · Cited by 87 · see citing works

Pharmaco-genetically guided treatment of recurrent rage outbursts in an adult male with 15q13.3 deletion syndrome

Cubells, J. F., DeOreo, E. H., Harvey, P. D., Garlow, S. J., Garber, K. B., Adam, M. P., & Martin, C. L. (2011) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33917 · Cited by 86 · see citing works

Disease-Modifying Approach to the Treatment of Alzheimerʼs Disease

Panza, F., Solfrizzi, V., Frisardi, V., Capurso, C. A., D’Introno, A., Colacicco, A. M., Vendemiale, G., Capurso, A., & Imbimbo, B. P. (2009) · Drugs & Aging · doi:10.2165/11315770-000000000-00000 · Cited by 86 · see citing works

Modulation of α7 Nicotinic Acetylcholine Receptor and Fibrillar Amyloid-β Interactions in Alzheimer's Disease Brain

Ni, R., Marutle, A., & Nordberg, A. K. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121447 · Cited by 83 · see citing works

REVIEW: γ‐Secretase Inhibitors for the Treatment of Alzheimer's Disease: The Current State

Panza, F., Frisardi, V., Imbimbo, B. P., Capurso, C. A., Logroscino, G., Sancarlo, D., Seripa, D., Vendemiale, G., Pilotto, A., & Solfrizzi, V. (2010) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2010.00164.x · Cited by 80 · see citing works

An open-label extension trial of galantamine in patients with probable vascular dementia and mixed dementia

Erkinjuntti, T., Kurz, A., Small, G. W., Bullock, R. A., Lilienfeld, S., & Damaraju, C. V. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80168-6 · Cited by 79 · see citing works

Galantamine anti-colitic effect: Role of alpha-7 nicotinic acetylcholine receptor in modulating Jak/STAT3, NF-κB/HMGB1/RAGE and p-AKT/Bcl-2 pathways

Wazea, S. A., Wadie, W., Bahgat, A. K., & El-Abhar, H. S. (2018) · Scientific Reports · doi:10.1038/s41598-018-23359-6 · Cited by 79 · see citing works

Synergistic neuroprotective effect of combined low concentrations of galantamine and melatonin against oxidative stress in SH‐SY5Y neuroblastoma cells

Romero, A., Egea, J., Garcı́a, A. G., & López, M. G. (2010) · Journal of Pineal Research · doi:10.1111/j.1600-079x.2010.00778.x · Cited by 79 · see citing works

An update on the pharmacology of galantamine

Villarroya, M., Garcı́a, A. G., Marco, J. L., & López, M. G. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1987 · Cited by 79 · see citing works

Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind investigation

SHARMA, T., REED, C., Aasen, I., & Kumari, V. (2006) · Schizophrenia Research · doi:10.1016/j.schres.2006.03.037 · Cited by 79 · see citing works

Development and validation of a GC–MS method for rapid determination of galanthamine in Leucojum aestivum and Narcissus ssp.: A metabolomic approach

Berkov, S. H., Bastida, J., Viladomat, F., & Codina, C. J. (2010) · Talanta · doi:10.1016/j.talanta.2010.11.029 · Cited by 78 · see citing works

Changes in cerebral neurotransmitters and metabolites induced by acute donepezil and memantine administrations: A microdialysis study

Shearman, E., Rossi, S., Szász, B. K., Jurányi, Z., Fallon, S. M., Pomara, N., Sershen, H. W., & Lajtha, Á. (2005) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2005.12.001 · Cited by 77 · see citing works

N-Alkylated galanthamine derivatives: Potent acetylcholinesterase inhibitors from Leucojum aestivum

Berkov, S. H., Codina, C. J., Viladomat, F., & Bastida, J. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.008 · Cited by 78 · see citing works

Current and Emerging Pharmacological Treatment Options for Dementia

Ringman, J. M., & Cummings, J. L. (2006) · Behavioural Neurology · doi:10.1155/2006/315386 · Cited by 76 · see citing works

Galantamine promotes adult hippocampal neurogenesis via M1 muscarinic and α7 nicotinic receptors in mice

Kita, Y., Ago, Y., Higashino, K., Asada, K., Takano, E., Takuma, K., & Matsuda, T. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000613 · Cited by 74 · see citing works

Rapid TLC/GC‐MS identification of acetylcholinesterase inhibitors in alkaloid extracts

Berkov, S. H., Bastida, J., Nikolova, M. T., Viladomat, F., & Codina, C. J. (2008) · Phytochemical Analysis · doi:10.1002/pca.1066 · Cited by 74 · see citing works

Alcohol use and the risk of developing Alzheimer's disease.

Tyas, S. L. (2001) · PubMed Central · Cited by 65 · see citing works

Galantamine and donepezil attenuate pharmacologically induced deficits in prepulse inhibition in rats

Hohnadel, E. J., Bouchard, K., & Terry, A. V. (2006) · Neuropharmacology · doi:10.1016/j.neuropharm.2006.08.025 · Cited by 65 · see citing works

Antioxidant Activity of Galantamine and Some of its Derivatives

Tsvetkova, D. D., Obreshkova, D. P., Zheleva‐Dimitrova, D., & Saso, L. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990148 · Cited by 65 · see citing works

Pharmacological and molecular enhancement of learning in aging and Alzheimer’s disease

Disterhoft, J. F., & Oh, M. M. (2006) · Journal of Physiology-Paris · doi:10.1016/j.jphysparis.2005.12.079 · Cited by 63 · see citing works

Cognitive Deficits in Schizophrenia: Focus on Neuronal Nicotinic Acetylcholine Receptors and Smoking

Ochoa, E. L. M., & Lasalde‐Dominicci, J. A. (2007) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-007-9149-x · Cited by 64 · see citing works

The rationale behind cholinergic drug treatment for dementia related to cerebrovascular disease

Grantham, C., & Geerts, H. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00274-5 · Cited by 64 · see citing works

Changes in brain 11C–nicotine binding sites in patients with mild Alzheimer’s disease following rivastigmine treatment as assessed by PET

Kadir, A., Darreh‐Shori, T., Almkvist, O., Wall, A. E., Långström, B., & Nordberg, A. K. (2007) · Psychopharmacology · doi:10.1007/s00213-007-0725-z · Cited by 63 · see citing works

The effects of galantamine treatment on caregiver time in Alzheimer's disease

Sano, M., Wilcock, G. K., van Baelen, B., & Kavanagh, S. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1000 · Cited by 62 · see citing works

Petrosamine, a potent anticholinesterase pyridoacridine alkaloid from a Thai marine sponge Petrosia n. sp

Nukoolkarn, V. S., Saen‐oon, S., Rungrotmongkol, T., Hannongbua, S. V., Ingkaninan, K., & Suwanborirux, K. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.05.027 · Cited by 61 · see citing works

Increased Sensitivity to Agonist-Induced Seizures, Straub Tail, and Hippocampal Theta Rhythm in Knock-In Mice Carrying Hypersensitive α4 Nicotinic Receptors

Fonck, C., Nashmi, R., Deshpande, P., Damaj, M. I., Marks, M. J., Riedel, A., Schwarz, J., Collins, A. C., Labarca, C. G., & Lester, H. A. (2003) · Journal of Neuroscience · doi:10.1523/jneurosci.23-07-02582.2003 · Cited by 69 · see citing works

Metabolic profiling of bioactive Pancratium canariense extracts by GC‐MS

Torras‐Claveria, L., Berkov, S. H., Jáuregui, O., Caujapé, J., Viladomat, F., Codina, C. J., & Bastida, J. (2009) · Phytochemical Analysis · doi:10.1002/pca.1158 · Cited by 61 · see citing works

Alkaloid Constituents of the Amaryllidaceae Plant Amaryllis belladonna L

Tallini, L. R., de Andrade, J. P., Kaiser, M., Viladomat, F., Nair, J. J., Zuanazzi, J. Â. S., & Bastida, J. (2017) · Molecules · doi:10.3390/molecules22091437 · Cited by 59 · see citing works

Nicotinic Acetylcholine Receptor Signaling in Neuroprotection

Akaike, A., Shimohama, S., & Misu, Y. (2018) · Springer eBooks · doi:10.1007/978-981-10-8488-1 · Cited by 60 · see citing works

The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease

Sabbagh, M. N., Lukas, R. J., Sparks, D. L., & Reid, R. T. (2002) · Journal of Alzheimer s Disease · doi:10.3233/jad-2002-4407 · Cited by 57 · see citing works

Mechanism of Action of Galantamine on N-Methyl-d-Aspartate Receptors in Rat Cortical Neurons

Moriguchi, S., Marszalec, W., Zhao, X., Yeh, J. Z., & Narahashi, T. (2004) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.067603 · Cited by 57 · see citing works

Positive allosteric modulators of alpha 7 nicotinic acetylcholine receptors reverse ketamine-induced schizophrenia-like deficits in rats

Nikiforuk, A., Kos, T., Hołuj, M., Potasiewicz, A., & Popik, P. (2015) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.07.034 · Cited by 55 · see citing works

GALANTAMINE: A REVIEW OF ITS USE IN ALZHEIMER'S DISEASE AND VASCULAR DEMENTIA

Corey, J. (2003) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2003.tb10467.x · Cited by 55 · see citing works

Long‐term safety and cognitive effects of galantamine in the treatment of probable vascular dementia or Alzheimer's disease with cerebrovascular disease

Kurz, A., Erkinjuntti, T., Small, G. W., Lilienfeld, S., & Damaraju, C. V. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00677.x · Cited by 54 · see citing works

Roles of Nicotinic Receptors in Acetylcholinesterase Inhibitor-Induced Neuroprotection and Nicotinic Receptor Up-Regulation

Takada‐Takatori, Y., Kume, T., Izumi, Y., Ohgi, Y., Niidome, T., Fujii, T., Sugimoto, H., & Akaike, A. (2009) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.32.318 · Cited by 53 · see citing works

Chronic Cerebral Hypoperfusion Accelerates Alzheimer’s Disease Pathology with Cerebrovascular Remodeling in a Novel Mouse Model

Zhai, Y., Yamashita, T., Nakano, Y., Sun, Z., Shang, J., Feng, T., Morihara, R., Fukui, Y., Ohta, Y., Hishikawa, N., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160345 · Cited by 54 · see citing works

Diastereoselective Total Synthesis of (±)‐Codeine

Varin, M., Barré, E., Iorga, B. I., & Guillou, C. (2008) · Chemistry - A European Journal · doi:10.1002/chem.200800744 · Cited by 53 · see citing works

Galantamine in the Treatment of Adult Autism: A Report of Three Clinical Cases

Hertzman, M. (2003) · The International Journal of Psychiatry in Medicine · doi:10.2190/je5q-1nft-fl40-7pmw · Cited by 53 · see citing works

Daffodils as potential crops of galanthamine. Assessment of more than 100 ornamental varieties for their alkaloid content and acetylcholinesterase inhibitory activity

Torras‐Claveria, L., Berkov, S. H., Codina, C. J., Viladomat, F., & Bastida, J. (2012) · Industrial Crops and Products · doi:10.1016/j.indcrop.2012.07.034 · Cited by 51 · see citing works

Cholinesterase Inhibition Activity, Alkaloid Profiling and Molecular Docking of Chilean Rhodophiala (Amaryllidaceae)

Tallini, L. R., Bastida, J., Cortés, N., Osorio, E. H., Theoduloz, C., & Schmeda‐Hirschmann, G. (2018) · Molecules · doi:10.3390/molecules23071532 · Cited by 51 · see citing works

Neural correlates of adjunctive rivastigmine treatment to antipsychotics in schizophrenia: A randomized, placebo-controlled, double-blind fMRI study

Kumari, V., Aasen, I., Ffytche, D. H., Williams, S., & Sharma, T. (2005) · NeuroImage · doi:10.1016/j.neuroimage.2005.08.013 · Cited by 50 · see citing works

The combination of memantine and galantamine improves cognition in rats: The synergistic role of the α7 nicotinic acetylcholine and NMDA receptors

Nikiforuk, A., Potasiewicz, A., Kos, T., & Popik, P. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.07.023 · Cited by 50 · see citing works

Beyond the neurotransmitter-focused approach in treating Alzheimer’s Disease: drugs targeting β-amyloid and tau protein

Panza, F., Solfrizzi, V., Frisardi, V., Imbimbo, B. P., Capurso, C. A., D’Introno, A., Colacicco, A. M., Seripa, D., Vendemiale, G., Capurso, A., et al. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03327445 · Cited by 48 · see citing works

Effect of galantamine on the human α7 neuronal nicotinic acetylcholine receptor, the Torpedo nicotinic acetylcholine receptor and spontaneous cholinergic synaptic activity

Texidó, L., Ros, E., Martı́n-Satué, M., López, S., Aleu, J., Marsal, J., & Solsona, C. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706221 · Cited by 47 · see citing works

Nicotinic receptor modulation: Advantages for successful Alzheimer’s disease therapy

Geerts, H., Finkel, L., Carr, R. A., & Spiros, Ä. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_19 · Cited by 40 · see citing works

Galantamine Is an Allosterically Potentiating Ligand of Neuronal Nicotinic but Not of Muscarinic Acetylcholine Receptors

Samochocki, M., Höffle‐Maas, A., Fehrenbacher, A., Jostock, R., Ludwig, J., Christner, C., Radina, M., Zerlin, M., Ullmer, C., Pereira, E. F. R., et al. (2003) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.102.045773 · Cited by 345 · see citing works

Beyond In Vitro Data: A Review of In Vivo Evidence Regarding the Allosteric Potentiating Effect of Galantamine on Nicotinic Acetylcholine Receptors in Alzheimer's Neuropathology

Coyle, J. T., Geerts, H., Sorra, K., & Amatniek, J. C. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11411 · Cited by 35 · see citing works

Nicotinic Cholinergic Modulation: Galantamine as a Prototype

Woodruff‐Pak, D. S., Lander, C., & Geerts, H. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00237.x · Cited by 61 · see citing works

Allosteric Modulation of Nicotinic Receptors as a Treatment Strategy for Alzheimer’s Disease

Maelicke, A. (2000) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000051227 · Cited by 105 · see citing works